All News
Burden of BMI on Costs of Musculoskeletal Diseases
A cross-sectional global study shows a substantial impact of obesity and BMI on the health and economic impact of patients with musculoskeletal (MSK) disorders.
Read Article
PsA Til Death Do Us Part (1.20.2023)
Dr. Jack Cush reviews the highlights from the past week on RheumNow.com.
Read Article
AS, but not PsA, has Increased Mortality Risk
A recent meta-analysis showed a significantly increased risk of overall mortality in ankylosing spondylitis (AS) but not psoriatic arthritis (PsA), largely associated with cardiovascular-specific mortality.
https://t.co/gnd0bMQIui https://t.co/sWFhJAIaGH
Links:
Dr. John Cush RheumNow ( View Tweet)
Phase III Trials Back Bimekizumab for Spondyloarthritis
Bimekizumab, an investigational biologic drug targeting interleukin (IL)-17A/F, appeared highly effective in patients with axial spondyloarthritis (axSpA), researchers said.
https://t.co/pdfxa3u29k https://t.co/0wLl48Fvj6
Links:
Dr. John Cush RheumNow ( View Tweet)
PRedSS was a small trial of 35 pts with early diffuss systemic sclerosis Rx w/ prednisolone(17) vs placebo(18). At 3 mos outcomes favored Pred, but nonsignificant (HAQ-DI -0.10; p= 0.25 & mRSS -3.90; p= 0.07), but less pain & anxiety https://t.co/iZw2L9SLhF https://t.co/2G2MuVMUSJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Danish registries stud of > 6 million persons finds 52898 new #IBD pts (over 18 yrs). Antibiotic exposure was assoc w/ increased risk of IBD, esp > 40 yrs. (40–60 yrs IRR 1.48; ≥60 yrs IRR 1.47) https://t.co/qU1OxXr7Gj https://t.co/YMh6L514By
Links:
Dr. John Cush RheumNow ( View Tweet)
New Hope for Hand Osteoarthritis
The drug talarozole – which increases retinoic acid – could be a promising new treatment for hand osteoarthritis.
https://t.co/AHoEZM75mh https://t.co/dZ1LWWoNl5
Links:
Dr. John Cush RheumNow ( View Tweet)
Elevated Uric Acid Is Associated With New‐Onset Atrial Fibrillation
A Longitudinal Swedish study has shown that elevated serum uric acid (SUA) levels has cardiovascular implications and may predict the development of atrial fibrillation (AFib).
https://t.co/5PIOC4ymhB https://t.co/HRAe2tIerJ
Links:
Dr. John Cush RheumNow ( View Tweet)
UK BADBIR cohort study of 9057 PsA & PsO pts. A greater comorbidity burden and work inability seen PsA vs PsO cohort. PsA (HR 1.98), female sex & depression (HR 1.21) were associated with shorter persistence on ustekinumab. https://t.co/aBILQqXDKl https://t.co/tLNIhnxdXO
Links:
Dr. John Cush RheumNow ( View Tweet)
Join us! Take advantage of our early bird pricing.
https://t.co/9Up0ZgaRP2
What attendees say about our meeting:
100% found the program free of commercial bias.
99% would recommend RheumNow Live to colleagues.
95% describe the content as extremely relevant to their practice. https://t.co/HOmh0CMyyJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Causes of Enthesitis: SpA (AS, reactive arthritis, PsA, enteropathic arthritis, ERA), JIA, but also in RA, leprosy, trauma, OA, DISH, acromegaly, fluorosis, retinoid therapy, hypo- or hyper-PTH, POEMS syndrome, X-linked hypophosphatemia https://t.co/pff2OWBT5C https://t.co/7zm2la4GtD
Links:
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib and RA-ILD
Dr. Richard Conway discusses Abstract 2251 at ACR22 Convergence. Abstract 2251: Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib
https://t.co/inndpqqbi8 https://t.co/8tRiKqT1x5
Links:
Dr. John Cush RheumNow ( View Tweet)
Ferritin may be more than biomarker in Stills, etc - may contribute directly to pathogenesis. Ferritin causes PMN activation & neutrophil extracellular traps (NETs). Could this be targeted therapeutically? https://t.co/yuvMaKqOa7 https://t.co/bjkEJvKH8d
Dr. John Cush RheumNow ( View Tweet)
Join RheumNow Live in person or virtually on 3/18 and 3/19. This meeting is unlike any other meeting you attended.
But don't take our word for it, last year's attendees say:
"Great conference. Best in the last year. I did Hopkins, CCR, and ACR too"
https://t.co/jvhKcVXNtz https://t.co/Hc6SzsPKNa
Links:
Dr. John Cush RheumNow ( View Tweet)
PsA Til Death Do Us Part
Dr. Jack Cush reviews the highlights from the past week on RheumNow
https://t.co/8km1IGdmkZ https://t.co/Drxqq1QYsC
Links:
Dr. John Cush RheumNow ( View Tweet)
Hydroxychloroquine Dose and Risk for Incident Retinopathy
A cohort study in Annals of Internal Medicine shows that higher hydroxychloroquine doses was associated with progressively greater risk for incident retinopathy.
https://t.co/DZ2UxDKgUD https://t.co/tFtNZc1Eza
Links:
Dr. John Cush RheumNow ( View Tweet)
Poorer health outcomes for at-risk patients with fractures
People at high risk of fracture are less likely to receive treatment for the underlying osteoporosis and also have poorer health outcomes.
https://t.co/XmFcnBf6US https://t.co/mgAkb0NLBv
Links:
Dr. John Cush RheumNow ( View Tweet)
Rx failures w/ nonmedical switching of biosimilars may be Nocebo effect. 140 #RA pts, 51 non-switchers & 89 switchers. Non-switchers more likely to improve than switchers (68 vs 26%, p < 0.001) and less likely to worsen (1% vs 9%, p < 0.01). https://t.co/w8lnv1V5Pi https://t.co/iT2RkkSosl
Links:
Dr. John Cush RheumNow ( View Tweet)
Naltrexone is indicated in opioid or EtOH dependence - not pain; yet it has wide off-label uses. Shown to be equal to Elavil in Rx of painful DM neuropathy; Little data from PBO RCTs in FM. Unclear how naltrexone modulates pain https://t.co/YZvfbHy9KJ https://t.co/6k9LfQSp1A
Links:
Dr. John Cush RheumNow ( View Tweet)
What RheumNow Live attendees say about our meeting:
"Great format w/shorter lectures, clinical content, good interface for audience participation to ask questions, and on-demand availability of videos post-meeting."
Join us!
https://t.co/AO0bqP5p54
@Janetbirdope @JoelKreme… https://t.co/d9ZhIbddgh
Links:
Dr. John Cush RheumNow ( View Tweet)